Publications by authors named "Jeff Sperinde"

Claim this Profile
P
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2 breast cancer that limits trastuzumab deruxtecan efficacy.
Dong Hu, Xiaoshuang Lyu, Zheqi Li, Prasanna Ekambaram, Anushka Dongre, Jeff Sperinde

Nat Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
Georgios Rigakos, Evangelia Razis, Georgia-Angeliki Koliou, Georgios Oikonomopoulos, Eleftheria Tsolaki, Jeff Sperinde

Anticancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
Jame Abraham, Albert J Montero, Rachel C Jankowitz, Mohamad Adham Salkeni, Jan H Beumer, Jeff Sperinde

J Clin Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p95HER2-T cell bispecific antibody for breast cancer treatment.
Irene Rius Ruiz, Rocio Vicario, Beatriz Morancho, Cristina Bernadó Morales, Enrique J Arenas, Jeff Sperinde

Sci Transl Med· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
Saranya Chumsri, Jeff Sperinde, Heshan Liu, Joseph Gligorov, Jean-Philippe Spano

Clin Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
Jeff Sperinde, Weidong Huang, Aki Vehtari, Ahmed Chenna, Pirkko-Liisa Kellokumpu-Lehtinen

Clin Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab.
Renata Duchnowska, Jeff Sperinde, Bogumiła Czartoryska-Arłukowicz, Paulina Myśliwiec, John Winslow

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.
Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Weidong Huang, Jodi M Weidler

Neuro Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.
Whitfield B Growdon, Jolijn Groeneweg, Virginia Byron, Celeste DiGloria, Darrell R Borger, Jeff Sperinde

Gynecol Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Denise A Yardley, Peter A Kaufman, Weidong Huang, Lea Krekow, Michael Savin, Jeff Sperinde

Breast Cancer Res· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, Jeff Sperinde, Dominique Agbor-Tarh

Clin Cancer Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Mojgan Haddad, Agnes Paquet

Clin Cancer Res· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
Filippo Montemurro, Aleix Prat, Valentina Rossi, Giorgio Valabrega, Jeff Sperinde

Mol Oncol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
Allan Lipton, Laurie Goodman, Kim Leitzel, Jennifer Cook, Jeff Sperinde

Breast Cancer Res Treat· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.
Renata Duchnowska, Wojciech Biernat, Barbara Szostakiewicz, Jeff Sperinde, Fanny Piette

Oncologist· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.
Roni Mamluk, Irvith M Carvajal, Brent A Morse, Henry Wong, Janette Abramowitz, Jeff Sperinde

MAbs· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.
Ritwik Ghosh, Archana Narasanna, Shizhen Emily Wang, Shuying Liu, Anindita Chakrabarty, Jeff Sperinde

Cancer Res· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Allan Lipton, Wolfgang J Köstler, Kim Leitzel, Suhail M Ali, Jeff Sperinde

Cancer· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Jeff Sperinde, Xueguang Jin, Jayee Banerjee, Elicia Penuel, Anasuya Saha

Clin Cancer Res· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer.
Masakazu Toi, Jeff Sperinde, Weidong Huang, Shigehira Saji, John Winslow

BMC Cancer· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.
Christine Desmedt, Jeff Sperinde, Fanny Piette, Weidong Huang, Xueguang Jin

Diagn Mol Pathol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
Yining Shi, Weidong Huang, Yuping Tan, Xueguang Jin, Rajiv Dua, Jeff Sperinde

Diagn Mol Pathol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exosome nanovesicles displaying G protein-coupled receptors for drug discovery.
Angeles Estelles, Jeff Sperinde, Thibaut Roulon, Barbara Aguilar, Caroline Bonner

Int J Nanomedicine· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis